-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhongguancun (000931.SZ) subsidiary company methylphenidate hydrochloride sustained-release chewable tablets approved for clinical trials

Zhitongcaijing·09/01/2026 09:09:06
Listen to the news

Zhitong Finance App News, Zhongguancun (000931.SZ) issued an announcement. The company's subsidiary, Beijing Huasu Pharmaceutical Co., Ltd. (abbreviation: Beijing Huasu), recently received methylphenidate hydrochloride sustained-release chewable tablets (specification: 40mg) “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration. The drug is intended to conduct clinical trials for attention deficit hyperactivity disorder (ADHD). Up to now, only 1 original research and import company in China has been approved for listing. Beijing Huasu is the first domestic company to be approved for clinical trials of this generic drug.